UCB Buys Rights To Anti-Epilepsy Nasal SprayBy
UCB has agreed to acquire from Proximagen, a Cambridge, UK-based pharmaceutical company, the rights to USL261, an investigational midazolam formulation as a nasal spray, as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.
The drug has been designed for intranasal delivery without active inhalation. It has been granted orphan-drug designation and fast-track designation by the US Food and Drug Administration.
Beyond this new addition and UCB’s current portfolio of products, UCB’s pipeline includes early candidates targeting drug-resistant epilepsy and infantile spasms.